With 53% institutional ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) is a favorite amongst the big guns | Nasdaq
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Seen as Takeover Target After Strong Cancer Drug Data - TheStreet
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology
Opinion: 5 biotech stocks that could be the next big winners - MarketWatch
Puma Biotech punts near $300 million on Takeda discard
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma and CANBridge cancel licensing deal for $20m
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
A Licensing Agreement Won't Protect This Biotech From A Takeover | Investor's Business Daily
Takeda farms out cancer drug alisertib to Puma Biotech | pharmaphorum
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Opinion: 15 biotech stocks to put on your watch list now - MarketWatch
10 Takeover Targets of 2018
